Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Autolus Therapeutics plc as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 94
- −1 vs. Q1 2025
- Shares held
- 166.0M
- −2.05M (−1.2%) vs. Q1 2025
- Total value
- $378.6M
- +$117.7M (+45.1%) vs. Q1 2025
- New holders
- 19
- 33 more added
- Sold out
- 20
- 26 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AUTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 83 | $212.0M |
| Q1 2026 | 84 | $184.4M |
| Q4 2025 | 89 | $277.1M |
| Q3 2025 | 96 | $235.7M |
| Q2 2025 | 94 | $378.6M |
| Q1 2025 | 95 | $261.0M |
| Q4 2024 | 110 | $395.4M |
| Q3 2024 | 101 | $648.5M |
| Q2 2024 | 111 | $620.0M |
| Q1 2024 | 120 | $1.12B |
| Q4 2023 | 99 | $746.6M |
| Q3 2023 | 71 | $258.1M |
| Q2 2023 | 69 | $260.4M |
| Q1 2023 | 65 | $195.1M |
| Q4 2022 | 71 | $204.2M |
| Q3 2022 | 66 | $105.7M |
| Q2 2022 | 67 | $143.9M |
| Q1 2022 | 66 | $228.6M |
| Q4 2021 | 73 | $272.3M |
| Q3 2021 | 59 | $164.2M |
| Q2 2021 | 69 | $169.6M |
| Q1 2021 | 63 | $129.4M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Autolus Therapeutics plc; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BIT Capital GmbH | 0 | $0 | 0.00% | −199,359−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −164,700−100.0% | Sold out |
| Vident Advisory, LLC | 0 | $0 | 0.00% | −155,504−100.0% | Sold out |
| Vontobel Holding Ltd. | 0 | $0 | 0.00% | −138,783−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −102,493−100.0% | Sold out |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd. | 0 | $0 | 0.00% | −89,949−100.0% | Sold out |
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −73,300−100.0% | Sold out |
| Exchange Traded Concepts, LLC | 0 | $0 | 0.00% | −69,993−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −51,188−100.0% | Sold out |
| Trust Co of Toledo NA | 0 | $0 | 0.00% | −36,265−100.0% | Sold out |
| Blair William & Co | 0 | $0 | 0.00% | −12,794−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −3,024−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −1,127−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −64−100.0% | Sold out |